Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Gary R. Hudes, Michael Anthony Carducci, Piotr Tomczak et al. · New England Journal of Medicine · 2007
BACKGROUND: Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease. METHODS: In this multicenter, phase 3 trial, we randomly assigned 626 patients with previously untreated, poor-prognosis metastatic renal-cell carcinoma to receive 25 mg of intravenous temsirolimus weekly, 3 million U of interferon alfa (with an increase to 18 million U) subcutaneously three times weekly, or combination therapy with 15 mg of temsirolimus weekly plus 6 million U of interferon alfa three times weekly. The primary end point was overall survival in comparisons of the temsirolimus group and the combination-therapy group with the interferon group. RESULTS: Patients who received temsirolimus alone had longer overall survival (hazard ratio for death, 0.73; 95% confidence interval [CI], 0.58 to 0.92; P=0.008) and progression-free survival (P<0.001) than did patients who received interferon alone. Overall survival in the combination-therapy group did not differ significantly from that in the interferon group (hazard ratio, 0.96; 95% CI, 0.76 to 1.20; P=0.70). Median overall survival times in the interferon group, the temsirolimus group, and the combination-therapy group were 7.3, 10.9, and 8.4 months, respectively. Rash, peripheral edema, hyperglycemia, and hyperlipidemia were more common in the temsirolimus group, whereas asthenia was more common in the interferon group. There were fewer patients with serious adverse events in the temsirolimus group than in the interferon group (P=0.02). CONCLUSIONS: As compared with interferon alfa, temsirolimus improved overall survival among patients with metastatic renal-cell carcinoma and a poor prognosis. The addition of temsirolimus to interferon did not improve survival. (ClinicalTrials.gov number, NCT00065468 [ClinicalTrials.gov].).
Cited by 3,647 works. doi:10.1056/nejmoa066838
Authors
- Gary R. Hudes
- Michael Anthony Carducci
- Piotr Tomczak
- Janice P. Dutcher
- Robert A. Figlin
- Anil Kapoor
- Elżbieta Starosławska
- Jeffrey Alan Sosman
- David F. McDermott
- I. Bodrogi
- Zoran Kovačević
- Vladimir Lesovoy
- Ingo G.H. Schmidt‐Wolf
- О. Л. Барбараш
- Erhan Gökmen
- Timothy E. O’Toole
- Stephanie Lustgarten
- Laurence Moore
- Robert John Motzer
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- A Multiple Testing Procedure for Clinical Trials
- Cancer Statistics, 2006
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
- Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
- TOR, a Central Controller of Cell Growth
- Upstream and downstream of mTOR
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma
- Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma
- Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.